343 related articles for article (PubMed ID: 29914442)
1. Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma progression by activating mTOR signaling pathway.
Liu H; Wang X; Feng B; Tang L; Li W; Zheng X; Liu Y; Peng Y; Zheng G; He Q
BMC Cancer; 2018 Jun; 18(1):661. PubMed ID: 29914442
[TBL] [Abstract][Full Text] [Related]
2. Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma cell aggressiveness by activating the NF-κB pathway.
Dai T; Zhang D; Cai M; Wang C; Wu Z; Ying Z; Wu J; Li M; Xie D; Li J; Song L
J Pathol; 2015 Feb; 235(3):490-501. PubMed ID: 25385148
[TBL] [Abstract][Full Text] [Related]
3. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
4. Bifunctional enzyme ATIC promotes propagation of hepatocellular carcinoma by regulating AMPK-mTOR-S6 K1 signaling.
Li M; Jin C; Xu M; Zhou L; Li D; Yin Y
Cell Commun Signal; 2017 Dec; 15(1):52. PubMed ID: 29246230
[TBL] [Abstract][Full Text] [Related]
5. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of GOLPH3 associated with the progression of gastric cancer: a preliminary study.
Peng J; Fang Y; Tao Y; Li K; Su T; Nong Y; Xie F; Lai M
PLoS One; 2014; 9(10):e107362. PubMed ID: 25286393
[TBL] [Abstract][Full Text] [Related]
7. High GOLPH3 expression is associated with poor prognosis and invasion of hepatocellular carcinoma.
Li Q; Ma Y; Xu W
Mol Med Rep; 2015 Jun; 11(6):4315-20. PubMed ID: 25634514
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
[TBL] [Abstract][Full Text] [Related]
9. GOLPH3 promotes cell proliferation and tumorigenicity in esophageal squamous cell carcinoma via mTOR and Wnt/β‑catenin signal activation.
Wang JH; Yuan LJ; Liang RX; Liu ZG; Li BH; Wen ZS; Huang ST; Zheng M
Mol Med Rep; 2017 Nov; 16(5):7138-7144. PubMed ID: 28901498
[TBL] [Abstract][Full Text] [Related]
10. LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway.
Ji J; Tang J; Deng L; Xie Y; Jiang R; Li G; Sun B
Oncotarget; 2015 Dec; 6(40):42813-24. PubMed ID: 26540343
[TBL] [Abstract][Full Text] [Related]
11. High expression of Golgi phosphoprotein-3 is associated with poor survival in patients with hepatocellular carcinoma.
Hu GS; Li YQ; Yang YM; Shi W; Liao AJ; Yao YH; Zeng B; Yuan J
Tumour Biol; 2014 Sep; 35(9):8625-32. PubMed ID: 24867097
[TBL] [Abstract][Full Text] [Related]
12. Down-Regulated NRSN2 Promotes Cell Proliferation and Survival Through PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma.
Wang X; Han L; Zhang J; Xia Q
Dig Dis Sci; 2015 Oct; 60(10):3011-8. PubMed ID: 26055238
[TBL] [Abstract][Full Text] [Related]
13. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
[TBL] [Abstract][Full Text] [Related]
14. GOLPH3 is a potential therapeutic target and a prognostic indicator of poor survival in bladder cancer treated by cystectomy.
Zhang Q; Zhuang J; Deng Y; Zhao X; Tang B; Yao D; Zhao W; Chang C; Lu Q; Chen W; Zhang S; Ji C; Cao L; Guo H
Oncotarget; 2015 Oct; 6(31):32177-92. PubMed ID: 26375441
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling.
Liu F; Zhang W; Yang F; Feng T; Zhou M; Yu Y; Yu X; Zhao W; Yi F; Tang W; Lu Y
Sci Rep; 2016 Feb; 6():21260. PubMed ID: 26879559
[TBL] [Abstract][Full Text] [Related]
16. SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway.
Zhou C; Liu C; Liu W; Chen W; Yin Y; Li CW; Hsu JL; Sun J; Zhou Q; Li H; Hu B; Fu P; Atyah M; Ma Q; Xu Y; Dong Q; Hung MC; Ren N
Theranostics; 2020; 10(10):4627-4643. PubMed ID: 32292519
[TBL] [Abstract][Full Text] [Related]
17. GOLP3 is a predictor of survival in patients with hepatocellular carcinoma.
JianXin J; Cha Y; ZhiPeng L; Jie X; Hao Z; Meiyuan C; ChengYi S
Clin Invest Med; 2014 Aug; 37(4):E233-42. PubMed ID: 25090263
[TBL] [Abstract][Full Text] [Related]
18. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
Zhang Z; Zhu J; Huang Y; Li W; Cheng H
Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
[TBL] [Abstract][Full Text] [Related]
19. Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway.
Ma X; Guo P; Qiu Y; Mu K; Zhu L; Zhao W; Li T; Han L
Oncotarget; 2016 Jun; 7(24):36185-36197. PubMed ID: 27167192
[TBL] [Abstract][Full Text] [Related]
20. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
